共 86 条
[1]
Bekaii-Saab T(2014)Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer Crit Rev Oncol Hematol 91 9-34
[2]
Wu C(2004)Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging J Natl Cancer Inst 96 1420-1425
[3]
O’Connell JB(2014)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 1065-1075
[4]
Maggard MA(2017)Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial JAMA 317 2392-2401
[5]
Ko CY(2015)First-line chemotherapy for mCRC—a review and evidence-based algorithm Nat Rev Clin Oncol 12 607-619
[6]
Heinemann V(2009)Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27 1829-1835
[7]
Weikersthal von LF(2005)Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 16 1311-1319
[8]
Decker T(2004)Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 644-657
[9]
Venook AP(2014)Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy Crit Rev Oncol Hematol 92 218-226
[10]
Niedzwiecki D(2007)Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 1670-1676